DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q2 2024 Earnings Conference Call August 8, 2024 8:00 AM ET

Company Participants

Rick Pauls - President, Chief Executive Officer & Director
Lorianne Masuoka - Chief Medical Officer
Scott Kellen - Chief Financial Officer & Company Secretary

Conference Call Participants

Thomas Flaten - Lake Street

Operator

Good morning ladies and gentlemen and welcome to the DiaMedica Therapeutics Second Quarter 2024 Conference Call. An audio recording of the webcast will be available shortly after the call today on DiaMedica's website at www.diamedica.com in the Investor Relations Section.

Before DiaMedica proceeds with its remarks, please note that the company will be making ford looking statements on today's call. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in these statements. For information, including factors that could cause actual results to differ from projected results appears in the section entitled Cautionary Statement Note regarding forward-looking statements in the company's press release issued yesterday and under the heading Risk Factors in DiaMedica's most recent annual report on Form 10-K and the second quarter report on Form 10-Q. DiaMedica's SEC filings are available at www.sec.gov and on its website. Please also note that any comments made on today's call speak only as of today, August 8, 2024 and may no longer be accurate at the time of any replay or transcript rereading. DiaMedica disclaims any duty to update its forward-looking statements. Following the prepared remarks, we will open the phone lines for questions.

I would now like to introduce your host for today's call, Mr. Rick Pauls, DiaMedica's President and Chief Executive Officer. Mr. Pauls, you may begin.

Rick Pauls

Thank you, operator. Hello, everyone and welcome to our second quarter conference call. I am joined this morning by Dr. Lorianne Masuoka, our Chief Medical Officer; and Scott Kellen, our Chief Financial Officer. We continue to make progress on our ReMEDy2 trial and we believe we're on track for the interim analysis. The level of interest from sites and potential investigators remains high and we will likely have to turn down some of the sites. I am grateful to our entire team. Everyone is working tirelessly to engage the highest quality research sites and facilitate their participation in the ReMEDy2 trial.

Let me turn you over to Lorianne for a brief update on our stroke program.

Lorianne Masuoka

Thanks, Rick. Let me start by echoing Rick's comments. We are making solid progress with our site activation activities and we are gaining a much welcome momentum for the ReMEDy2 trial. Moving sites to the start-up process continues to be very challenging. We believe this is due to the effects of continued staffing shortages at research hospitals. We believe that much of the momentum gain is related to increasingly using our people to lead direct communications with the study sites.